Human Retroviral Infections Immunological and Therapeutic Control / edited by Kenneth E. Ugen, Mauro Bendinelli, Herman Friedman.

The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquire...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Ugen, Kenneth E. (Editor), Bendinelli, Mauro (Editor), Friedman, Herman (Editor)
Format: eBook
Language:English
Published: New York, NY : Springer US : Imprint: Springer, 2002.
Edition:1st ed. 2002.
Series:Infectious Agents and Pathogenesis,
Springer eBook Collection.
Subjects:
Online Access:Click to view e-book
Holy Cross Note:Loaded electronically.
Electronic access restricted to members of the Holy Cross Community.

MARC

LEADER 00000nam a22000005i 4500
001 b3239405
003 MWH
005 20191023162350.0
007 cr nn 008mamaa
008 100301s2002 xxu| s |||| 0|eng d
020 |a 9780306468193 
024 7 |a 10.1007/b111099  |2 doi 
035 |a (DE-He213)978-0-306-46819-3 
050 4 |a E-Book 
072 7 |a MJCJ  |2 bicssc 
072 7 |a MED022090  |2 bisacsh 
072 7 |a MJCJ  |2 thema 
245 1 0 |a Human Retroviral Infections  |h [electronic resource] :  |b Immunological and Therapeutic Control /  |c edited by Kenneth E. Ugen, Mauro Bendinelli, Herman Friedman. 
250 |a 1st ed. 2002. 
264 1 |a New York, NY :  |b Springer US :  |b Imprint: Springer,  |c 2002. 
300 |a XXII, 368 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Infectious Agents and Pathogenesis,  |x 1075-1289 
490 1 |a Springer eBook Collection 
505 0 |a The Two Principal Viremias of HIV -- Potential Role of Human T-cell Leukemia/Lymphoma Viruses (HTLV) in Diseases Other Than Acute T-cell Leukemia/Lymphoma (ATL) -- Viral-Related Proteins in Immune Dysfunction Associated with AIDS -- Carbohydrate Interactions and HIV-1 -- HTLV-I and HTLV-II Infection -- Vaccine Approaches for Human T-cell Lymphotropic Virus Type I -- Immune Responses againstHIV-2 -- HIV Mucosal Vaccines -- Nucleic Acid Vaccination against HIV-1 -- Passive Immunotherapy against HIV-1 -- Human Immunodeficiency Virus Type 1 Accessory Genes -- A New Generation of Antiviral Therapeutics Designed to Prevent the Use of Chemokine Receptors for Entry by HIV-1 -- Protease Inhibitors and HIV-1 Genetic Variability in Infected Children -- Gene Therapy and HIV-1 Infection -- Pediatric HIV. 
520 |a The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established “cure” for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability. 
590 |a Loaded electronically. 
590 |a Electronic access restricted to members of the Holy Cross Community. 
650 0 |a Infectious diseases. 
650 0 |a Medical microbiology. 
650 0 |a Immunology. 
650 0 |a Pathology. 
650 0 |a Laboratory medicine. 
650 0 |a Human anatomy. 
690 |a Electronic resources (E-books) 
700 1 |a Ugen, Kenneth E.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Bendinelli, Mauro.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Friedman, Herman.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
830 0 |a Infectious Agents and Pathogenesis,  |x 1075-1289 
830 0 |a Springer eBook Collection. 
856 4 0 |u https://holycross.idm.oclc.org/login?auth=cas&url=https://doi.org/10.1007/b111099  |3 Click to view e-book  |t 0 
907 |a .b32394056  |b 04-18-22  |c 02-26-20 
998 |a he  |b 02-26-20  |c m  |d @   |e -  |f eng  |g xxu  |h 0  |i 1 
912 |a ZDB-2-SBL 
912 |a ZDB-2-BAE 
950 |a Biomedical and Life Sciences (Springer-11642) 
902 |a springer purchased ebooks 
903 |a SEB-COLL 
945 |f  - -   |g 1  |h 0  |j  - -   |k  - -   |l he   |o -  |p $0.00  |q -  |r -  |s b   |t 38  |u 0  |v 0  |w 0  |x 0  |y .i21525705  |z 02-26-20 
999 f f |i 1e36a93d-21af-5037-ae4c-0a426550decf  |s 8c2eba44-505e-5433-8318-a17ec1c77499  |t 0 
952 f f |p Online  |a College of the Holy Cross  |b Main Campus  |c E-Resources  |d Online  |t 0  |e E-Book  |h Library of Congress classification  |i Elec File